Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Celsion Corporation CLSN
$1.95
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
14471628.00000000
-
week52high
-
week52low
-
Revenue
500000
-
P/E TTM
-1
-
Beta
2.25649200
-
EPS
-3.96800000
-
Last Dividend
0.00000000
-
Next Earnings Date
29 мар 2023 г. в 04:00
Описание компании
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 13 апр 2022 г. | |
| Oppenheimer | Perform | Outperform | 16 июл 2020 г. |
| Oppenheimer | Outperform | 22 ноя 2017 г. | |
| Oppenheimer | Outperform | 21 ноя 2017 г. | |
| Maxim Group | Buy | Hold | 05 окт 2017 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Dentzer James E | A | 2667 | 2667 | 30 сент 2022 г. |
| Le Goff Corinne | A | 177000 | 177000 | 18 июл 2022 г. |
| Le Goff Corinne | A | 53000 | 53000 | 18 июл 2022 г. |
| Kardaras Constantine John | A | 5833 | 1750 | 13 июн 2022 г. |
| Tumminello Timothy J | A | 29300 | 7500 | 13 июн 2022 г. |
| Fritz Frederick J. | A | 27004 | 7500 | 13 июн 2022 г. |
| Chow Pok Yu Augustine | A | 27242 | 7500 | 13 июн 2022 г. |
| Lindborg Stacy | A | 7666 | 2500 | 13 июн 2022 г. |
| Hooper Robert W | A | 26978 | 7500 | 13 июн 2022 г. |
| Pellizzari Christine A | A | 7666 | 2500 | 13 июн 2022 г. |
Новостная лента
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.
GlobeNewsWire
12 сент 2022 г. в 18:30
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here.
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
07 сент 2022 г. в 09:15
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will be held from September 12-14 with in-person participation held at the Lotte New York Palace Hotel.
Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
15 авг 2022 г. в 15:31
Celsion Corporation (NASDAQ:CLSN ) Q2 2022 Earnings Conference Call August 15, 2022 11:00 AM ET Company Participants Monique Kosse - IR, LifeSci Advisors Michael Tardugno - Executive Chairman Corinne Le Goff - President & CEO Jeffrey Church - CFO Nicholas Borys - CMO Khursheed Anwer - Chief Science Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Kumar Raja - Brookline Capital Markets David Bautz - Zacks Small-Cap Research Operator Good morning, and welcome to Celsion's Second Quarter 2022 Earnings Call.
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
GlobeNewsWire
08 авг 2022 г. в 08:30
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines.
Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2022 Results - Earnings Call Transcript
Seeking Alpha
16 мая 2022 г. в 15:26
Celsion Corporation (NASDAQ:CLSN ) Q1 2022 Earnings Conference Call May 16, 2022 11:00 AM ET Company Participants Monique Kosse - Investor Relations Michael Tardugno - Chairman, Chief Executive Officer and President Jeff Church - Chief Financial Officer Nicholas Borys - Chief Medical Officer Khursheed Anwer - Chief Science Officer Conference Call Participants Emily Bodnar - H.C. Wainwright David Bautz - Zacks Small-Cap Research Operator Good day, everyone and welcome to Celsion's First Quarter 2022 Earnings Call.